JP2018502572A5 - - Google Patents

Download PDF

Info

Publication number
JP2018502572A5
JP2018502572A5 JP2017534345A JP2017534345A JP2018502572A5 JP 2018502572 A5 JP2018502572 A5 JP 2018502572A5 JP 2017534345 A JP2017534345 A JP 2017534345A JP 2017534345 A JP2017534345 A JP 2017534345A JP 2018502572 A5 JP2018502572 A5 JP 2018502572A5
Authority
JP
Japan
Prior art keywords
antibody
seq
bispecific antibody
polypeptide
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2017534345A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018502572A (ja
JP6744313B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2015/068238 external-priority patent/WO2016109774A1/en
Publication of JP2018502572A publication Critical patent/JP2018502572A/ja
Publication of JP2018502572A5 publication Critical patent/JP2018502572A5/ja
Application granted granted Critical
Publication of JP6744313B2 publication Critical patent/JP6744313B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2017534345A 2015-01-02 2015-12-31 血漿カリクレインおよび第ｘｉｉ因子に対する二重特異性抗体 Active JP6744313B2 (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201562099236P 2015-01-02 2015-01-02
US62/099,236 2015-01-02
US201562200363P 2015-08-03 2015-08-03
US62/200,363 2015-08-03
US201562261609P 2015-12-01 2015-12-01
US62/261,609 2015-12-01
PCT/US2015/068238 WO2016109774A1 (en) 2015-01-02 2015-12-31 Bispecific antibodies against plasma kallikrein and factor xii

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2020128994A Division JP7003347B2 (ja) 2015-01-02 2020-07-30 血漿カリクレインおよび第ｘｉｉ因子に対する二重特異性抗体

Publications (3)

Publication Number Publication Date
JP2018502572A JP2018502572A (ja) 2018-02-01
JP2018502572A5 true JP2018502572A5 (cg-RX-API-DMAC7.html) 2019-02-14
JP6744313B2 JP6744313B2 (ja) 2020-08-26

Family

ID=56285069

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2017534345A Active JP6744313B2 (ja) 2015-01-02 2015-12-31 血漿カリクレインおよび第ｘｉｉ因子に対する二重特異性抗体
JP2020128994A Active JP7003347B2 (ja) 2015-01-02 2020-07-30 血漿カリクレインおよび第ｘｉｉ因子に対する二重特異性抗体
JP2021150755A Active JP7241827B2 (ja) 2015-01-02 2021-09-16 血漿カリクレインおよび第ｘｉｉ因子に対する二重特異性抗体
JP2023035060A Active JP7635285B2 (ja) 2015-01-02 2023-03-07 血漿カリクレインおよび第ｘｉｉ因子に対する二重特異性抗体

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2020128994A Active JP7003347B2 (ja) 2015-01-02 2020-07-30 血漿カリクレインおよび第ｘｉｉ因子に対する二重特異性抗体
JP2021150755A Active JP7241827B2 (ja) 2015-01-02 2021-09-16 血漿カリクレインおよび第ｘｉｉ因子に対する二重特異性抗体
JP2023035060A Active JP7635285B2 (ja) 2015-01-02 2023-03-07 血漿カリクレインおよび第ｘｉｉ因子に対する二重特異性抗体

Country Status (13)

Country Link
US (2) US11390687B2 (cg-RX-API-DMAC7.html)
EP (2) EP3240570B1 (cg-RX-API-DMAC7.html)
JP (4) JP6744313B2 (cg-RX-API-DMAC7.html)
KR (2) KR102670705B1 (cg-RX-API-DMAC7.html)
CN (2) CN114316061B (cg-RX-API-DMAC7.html)
AU (2) AU2015373910B2 (cg-RX-API-DMAC7.html)
CA (1) CA2972800A1 (cg-RX-API-DMAC7.html)
CO (1) CO2017007123A2 (cg-RX-API-DMAC7.html)
EA (1) EA201791527A1 (cg-RX-API-DMAC7.html)
IL (2) IL298086B2 (cg-RX-API-DMAC7.html)
MX (2) MX2017008541A (cg-RX-API-DMAC7.html)
NZ (1) NZ771568A (cg-RX-API-DMAC7.html)
WO (1) WO2016109774A1 (cg-RX-API-DMAC7.html)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL298086B2 (en) 2015-01-02 2024-11-01 Takeda Pharmaceuticals Co Bispecific antibodies against plasma kallikrein and factor xii
EP3325516B1 (en) * 2015-07-21 2021-12-15 Takeda Pharmaceutical Company Limited A monoclonal antibody inhibitor of factor xiia
IL315175A (en) * 2016-09-16 2024-10-01 Takeda Pharmaceuticals Co RNA biomarkers for hereditary angioedema
CA3221995C (en) 2017-02-08 2024-05-28 Dragonfly Therapeutics, Inc. Multi-specific binding proteins for activation of natural killer cells and therapeutic uses thereof to treat cancer
SG11201907646YA (en) 2017-02-20 2019-09-27 Dragonfly Therapeutics Inc Proteins binding her2, nkg2d and cd16
EP3668893A4 (en) * 2017-08-16 2021-08-04 Dragonfly Therapeutics, Inc. PROTEINS BINDING TO NKG2D, CD16 AND EGFR, HLA-E, CCR4, OR PD-L1
BR112020007405A2 (pt) * 2017-10-18 2020-12-08 Regenxbio Inc. Produtos terapêuticos de anticorpo pós-translacionalmente modificados totalmente humanos
JP7394767B2 (ja) * 2018-01-12 2023-12-08 ジェンザイム・コーポレーション ポリペプチドの定量化方法
KR20200118824A (ko) 2018-02-08 2020-10-16 드래곤플라이 쎄라퓨틱스, 인크. 자연 살해 세포를 활성화시키는 다중-특이성 결합 단백질을 수반하는 암의 병용 요법
PT3749346T (pt) 2018-02-08 2024-09-05 Dragonfly Therapeutics Inc Combinações de domínios variáveis de anticorpos dirigidas ao receptor nkg2d
CA3091424A1 (en) * 2018-02-20 2019-08-29 Dragonfly Therapeutics, Inc. Multi-specific binding proteins that bind cd33, nkg2d, and cd16, and methods of use
EP3805386A4 (en) * 2018-06-08 2022-03-23 Modalis Therapeutics Corporation MODIFIED CAS9 PROTEIN AND USE THEREOF
CA3106108A1 (en) * 2018-07-11 2020-01-16 Momenta Pharmaceuticals, Inc. Compositions and methods related to engineered fc-antigen binding domain constructs targeted to pd-l1
AU2019318083A1 (en) * 2018-08-08 2021-02-25 Dragonfly Therapeutics, Inc. Multi-specific binding proteins that bind BCMA, NKG2D and CD16, and methods of use
AU2019319906A1 (en) * 2018-08-08 2021-03-04 Dragonfly Therapeutics, Inc. Proteins binding NKG2D, CD16 and a tumor-associated antigen
EA202091888A1 (ru) 2018-08-08 2020-10-23 Драгонфлай Терапьютикс, Инк. Вариабельные домены антител, нацеленные на рецептор nkg2d
CA3108646A1 (en) * 2018-08-08 2020-02-13 Dragonfly Therapeutics, Inc. Proteins binding nkg2d, cd16 and a tumor-associated antigen
WO2020086741A1 (en) * 2018-10-24 2020-04-30 Shire-Nps Pharmaceuticals, Inc. Glp-2 fusion polypeptides and uses for treating and preventing gastrointestinal conditions
MX2022001049A (es) * 2019-07-26 2022-05-03 Janssen Biotech Inc Proteínas que comprenden dominios de unión al antígeno de la peptidasa 2 relacionada con la calicreína y sus usos.
MX2022013944A (es) 2020-05-06 2022-11-30 Dragonfly Therapeutics Inc Proteinas que se unen al receptor activador de celulas asesinas naturales grupo 2 miembro d (nkg2d), cumulo de diferenciacion (cd16) y miembro a de la familia de dominios de lectina tipo c 12 (clec12a).
WO2022094255A2 (en) * 2020-10-29 2022-05-05 Regenxbio Inc. Vectorized factor xii antibodies and administration thereof
CN114790245A (zh) * 2021-01-25 2022-07-26 成都康弘生物科技有限公司 一种抗体及其用途
CN114790246A (zh) * 2021-01-25 2022-07-26 成都康弘生物科技有限公司 一种抗体及其用途
JP2024508894A (ja) 2021-03-03 2024-02-28 ドラゴンフライ セラピューティクス， インコーポレイテッド Ｎｋｇ２ｄ、ｃｄ１６、及び腫瘍関連抗原に結合する多特異性結合タンパク質を使用して癌を治療する方法
CN115925967A (zh) * 2021-04-22 2023-04-07 广东菲鹏制药股份有限公司 双特异性多功能融合多肽
WO2024238407A2 (en) * 2023-05-12 2024-11-21 Arizona Board Of Regents On Behalf Of The University Of Arizona Methods of treating dilated cardiomyopathy and heart failure

Family Cites Families (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
US4777127A (en) 1985-09-30 1988-10-11 Labsystems Oy Human retrovirus-related products and methods of diagnosing and treating conditions associated with said retrovirus
GB8702816D0 (en) 1987-02-07 1987-03-11 Al Sumidaie A M K Obtaining retrovirus-containing fraction
US5219740A (en) 1987-02-13 1993-06-15 Fred Hutchinson Cancer Research Center Retroviral gene transfer into diploid fibroblasts for gene therapy
US5422120A (en) 1988-05-30 1995-06-06 Depotech Corporation Heterovesicular liposomes
AP129A (en) 1988-06-03 1991-04-17 Smithkline Biologicals S A Expression of retrovirus gag protein eukaryotic cells
US4963657A (en) 1988-06-09 1990-10-16 Temple University Of The Commonwealth System Of Higher Education Monoclonal antibodies to the light chain region of human factor XII and methods of preparing and using the same
WO1990007936A1 (en) 1989-01-23 1990-07-26 Chiron Corporation Recombinant therapies for infection and hyperproliferative disorders
GB8901859D0 (en) 1989-01-27 1989-03-15 Shield Diagnostics Limited Diagnostic test
US5500349A (en) 1989-01-27 1996-03-19 Coagen Limited Blood-coagulation factor XIIA β monoclonal antibody and immunoassay
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
ES2200016T3 (es) 1989-03-21 2004-03-01 Vical Incorporated Expresion de secuencias polinucleotidicas exogenas en un vertebrado.
WO1991002805A2 (en) 1989-08-18 1991-03-07 Viagene, Inc. Recombinant retroviruses delivering vector constructs to target cells
US5585362A (en) 1989-08-22 1996-12-17 The Regents Of The University Of Michigan Adenovirus vectors for gene therapy
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
NZ237464A (en) 1990-03-21 1995-02-24 Depotech Corp Liposomes with at least two separate chambers encapsulating two separate biologically active substances
AU7793291A (en) 1990-05-10 1991-11-27 Cetus Corporation Inhibitors of factor xii activation and applications thereof
ES2197145T3 (es) 1991-08-20 2004-01-01 The Government Of The Usa As Represented By The Secretary Of The Deptm. Of Health And Human Services Transferencia de genes mediada por adenovirus al gastrointestinal.
WO1993010218A1 (en) 1991-11-14 1993-05-27 The United States Government As Represented By The Secretary Of The Department Of Health And Human Services Vectors including foreign genes and negative selective markers
GB9125623D0 (en) 1991-12-02 1992-01-29 Dynal As Cell modification
US6093399A (en) * 1992-03-05 2000-07-25 Board Of Regents, The University Of Texas System Methods and compositions for the specific coagulation of vasculature
FR2688514A1 (fr) 1992-03-16 1993-09-17 Centre Nat Rech Scient Adenovirus recombinants defectifs exprimant des cytokines et medicaments antitumoraux les contenant.
WO1993025234A1 (en) 1992-06-08 1993-12-23 The Regents Of The University Of California Methods and compositions for targeting specific tissue
JPH09507741A (ja) 1992-06-10 1997-08-12 アメリカ合衆国 ヒト血清による不活性化に耐性のあるベクター粒子
GB2269175A (en) 1992-07-31 1994-02-02 Imperial College Retroviral vectors
JPH08503855A (ja) 1992-12-03 1996-04-30 ジェンザイム・コーポレイション 嚢胞性線維症に対する遺伝子治療
US5981568A (en) 1993-01-28 1999-11-09 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
EP0695169B1 (en) 1993-04-22 2002-11-20 SkyePharma Inc. Multivesicular cyclodextrin liposomes encapsulating pharmacologic compounds and methods for their use
AU687829B2 (en) 1993-06-24 1998-03-05 Advec, Inc. Adenovirus vectors for gene therapy
DE69433461T2 (de) 1993-09-15 2004-11-18 Chiron Corp. (N.D.Ges.D. Staates Delaware), Emeryville Rekombinanter Alphavirus Vektor
US6015686A (en) 1993-09-15 2000-01-18 Chiron Viagene, Inc. Eukaryotic layered vector initiation systems
HU223733B1 (hu) 1993-10-25 2004-12-28 Canji, Inc. Rekombináns adenovírus vektor és eljárás alkalmazására
KR100241300B1 (ko) 1993-11-16 2000-03-02 Sheldon A. Schaffer 활성물질의 조절된 방출성을 갖는 소포
CA2158977A1 (en) 1994-05-09 1995-11-10 James G. Respess Retroviral vectors having a reduced recombination rate
WO1996017072A2 (en) 1994-11-30 1996-06-06 Chiron Viagene, Inc. Recombinant alphavirus vectors
GB9609262D0 (en) 1996-05-02 1996-07-03 Isis Innovation Peptide library and method
AU2998597A (en) 1996-05-06 1997-11-26 Chiron Corporation Crossless retroviral vectors
WO2000053211A2 (en) 1999-03-09 2000-09-14 University Of Southern California Method of promoting myocyte proliferation and myocardial tissue repair
CN101260156A (zh) * 2002-06-28 2008-09-10 多曼蒂斯有限公司 免疫球蛋白单个变体抗原结合区及其特异性构建体
PL1830924T3 (pl) 2004-12-23 2013-08-30 Csl Behring Gmbh Zapobieganie tworzeniu i/lub stabilizacji skrzepu
GB0500487D0 (en) 2005-01-11 2005-02-16 Axis Shield Diagnostics Ltd Forms of factor XIIa
US7932021B2 (en) 2005-07-28 2011-04-26 American Diagnostica, Inc. Lupus anticoagulant testing
GB0607515D0 (en) 2006-04-13 2006-05-24 Axis Shield Diagnostics Ltd Anti-factor xlla therapy
TWI465247B (zh) 2008-04-11 2014-12-21 Catalyst Biosciences Inc 經修飾的因子ｖｉｉ多肽和其用途
TWI496582B (zh) * 2008-11-24 2015-08-21 必治妥美雅史谷比公司 雙重專一性之ｅｇｆｒ／ｉｇｆｉｒ結合分子
EP2373691B1 (en) 2008-12-18 2019-01-23 Oregon Health&Science University Anti-fxi antibodies and methods of use
SI3459564T1 (sl) 2010-01-06 2022-06-30 Takeda Pharmaceutical Company Limited Proteini, ki vežejo plazemski kalikrein
CN103298937B (zh) 2010-11-17 2016-05-25 中外制药株式会社 具有代替凝血因子viii的功能的功能的多特异性抗原结合分子
JP2014506257A (ja) * 2011-01-06 2014-03-13 ダイアックス コーポレーション 血漿カリクレイン結合タンパク質
MX347454B (es) * 2011-07-22 2017-04-27 Csl Ltd Anticuerpos monoclonales inhibidores anti-factor xii-xiia.
EP2548892A1 (en) * 2011-07-22 2013-01-23 CSL Behring GmbH Inhibitory anti-Factor XII/XIIa monoclonal Antibodies and their uses
JP5653860B2 (ja) 2011-07-28 2015-01-14 富士フイルム株式会社 管壁の硬度測定方法および装置
US20150299313A1 (en) * 2011-10-05 2015-10-22 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule for promoting clearance from plasma of antigen comprising suger chain receptor-binding domain
ES2816078T3 (es) * 2011-12-20 2021-03-31 Medimmune Llc Polipéptidos modificados para armazones de anticuerpo biespecífico
EP2623110A1 (en) * 2012-01-31 2013-08-07 CSL Behring GmbH Factor XII inhibitors for the treatment of neurological inflammatory disorders
WO2013167669A1 (en) 2012-05-10 2013-11-14 Bayer Pharma Aktiengesellschaft Antibodies capable of binding to the coagulation factor xi and/or its activated form factor xia and uses thereof
WO2014019644A1 (en) * 2012-07-31 2014-02-06 Baxter International Inc. Selective measurement of active human protease coagulation factors
WO2014089493A1 (en) 2012-12-07 2014-06-12 Vanderbilt University Antibodies against factor xii and uses thereof
JP6656926B2 (ja) 2013-01-20 2020-03-04 ダイアックス コーポレーション ｐＫａｌ関連疾病の評価、アッセイおよび治療
CN111704672B (zh) * 2013-03-15 2024-06-04 武田药品工业株式会社 抗血浆激肽释放酶抗体
JP2017501968A (ja) * 2013-06-28 2017-01-19 ツェー・エス・エル・ベーリング・ゲー・エム・ベー・ハー 第ｘｉｉ因子インヒビターおよびｃ１−インヒビターを使用する組合せ療法
EP4067383A1 (en) * 2013-07-25 2022-10-05 Cytomx Therapeutics Inc. Multispecific antibodies, multispecific activatable antibodies and methods of using the same
IL298086B2 (en) 2015-01-02 2024-11-01 Takeda Pharmaceuticals Co Bispecific antibodies against plasma kallikrein and factor xii
EP3325516B1 (en) 2015-07-21 2021-12-15 Takeda Pharmaceutical Company Limited A monoclonal antibody inhibitor of factor xiia
EP3263803B1 (en) 2016-06-30 2019-08-14 ABB Schweiz AG Substation

Similar Documents

Publication Publication Date Title
JP2018502572A5 (cg-RX-API-DMAC7.html)
JP2020186248A5 (cg-RX-API-DMAC7.html)
CN106459220B (zh) 适用于高通量筛选的新的双特异性形式
US11286312B2 (en) Multispecific antibodies
JP2016533174A5 (cg-RX-API-DMAC7.html)
KR102282691B1 (ko) 개변된 헬퍼 파지를 사용하여 항원 결합 분자를 제작하는 방법
JP7203800B2 (ja) ヌクレオチド・ライブラリー
JP7549961B2 (ja) 少なくともｃｄ３及びｈｓａを標的とするヘテロ二量体多重特異性抗体フォーマット
JP2017512063A5 (cg-RX-API-DMAC7.html)
JP7209464B2 (ja) ヒトインターロイキン－２に対する免疫刺激性モノクローナル抗体
JP2017529067A5 (cg-RX-API-DMAC7.html)
JP2017509335A5 (cg-RX-API-DMAC7.html)
CN108473554A (zh) 多特异性抗体
JP2020500510A5 (cg-RX-API-DMAC7.html)
JP2014518883A5 (cg-RX-API-DMAC7.html)
JP2014521313A5 (cg-RX-API-DMAC7.html)
JP2019506839A5 (cg-RX-API-DMAC7.html)
JP2018512124A5 (cg-RX-API-DMAC7.html)
KR20190111946A (ko) 1가 항-프로페르딘 항체 및 항체 단편
CN111526887A (zh) 用于使血清中的蛋白质半衰期增加的组合物和方法
RU2017134043A (ru) Модифицированные антитела igg, которые связываются с трансформирующим фактором роста бета-1 с высокой аффинностью, авидностью и специфичностью
CN104955846B (zh) 人源化抗hmgb1抗体或其抗原结合性片段
Henry et al. A disulfide-stabilized human VL single-domain antibody library is a source of soluble and highly thermostable binders
Aoki et al. Engineering a low-immunogenic mirror-image VHH against vascular endothelial growth factor
CN107073093A (zh) 亲和蛋白及其用途